Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?-Reference-Cited by-同舟云学术

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Published:2021-09-22 Issue:20 Volume:10 Page:6959-6970
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Canet Jim¹²³^ORCID,Cony‐Makhoul Pascale⁴^ORCID,Orazio Sébastien¹²,Cornet Edouard⁵^ORCID,Troussard Xavier⁵^ORCID,Maynadié Marc⁶,Étienne Gabriel⁴⁷^ORCID,Monnereau Alain¹²^ORCID

Affiliation:

1. Bordeaux Population Health Research Center Inserm UMR1219‐EPICENE University of Bordeaux Bordeaux France

2. Registre des Hémopathies Malignes de la Gironde Institut Bergonié, Centre de lutte Contre le Cancer Bordeaux France

3. IQVIA Bordeaux France

4. FiLMC GroupCentre Léon Bérard 28 Prom. Léa et Napoléon Bullukian Lyon Cedex 8 France

5. Registre régional des Hémopathies Malignes de Basse‐Normandie (RRHMBN) CHU Caen Caen France

6. Registre des Hémopathies Malignes de Côte‐d’Or CHU Dijon‐Bourgogne – Université de Bourgogne INSERM U1231 Dijon France

7. Service d'hématologie Institut Bergonié, Centre de lutte Contre le Cancer Bordeaux France

Funder

Ligue Contre le Cancer

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4186

Reference31 articles.

1. Épidémiologie descriptive des cancers en France métropolitaine : incidence, survie et prévalence

2. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

3. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

4. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

5. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data;Cancer Medicine;2024-09

2. Exploration of treatment‐free remission in CML, based on molecular monitoring;Cancer Medicine;2023-12-22

3. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML;Cancer;2023-06-24

4. Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials;Annals of Hematology;2023-04-20

5. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer;Frontiers in Pharmacology;2022-12-12